Sandra Rubio, MD
Endocrinology, Diabetes & Metabolism · Cottonwood, AZNPI 1225131014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,712 of the $34,385 with a category attached, or 71.9%. 22 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 56.7% of the total. Reporting peaked in 2019 at $13,613 and has fallen 99.4% since, to $83 in 2025. Among endocrinology, diabetes & metabolism clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $151.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$19K
- Amgen$9K
- Corcept Therapeutics$4K
- Medtronic$536
- Novo Nordisk$429
- AstraZeneca$261
- plus $952 from 16 others
What the payments were for
- Consulting fees$2,2507%
- Speaking & faculty fees$24,71272%
- Travel & lodging$2,6088%
- Food & beverage$4,55913%
- Education$2551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 74 | $19,492 |
| Amgen(2 entities) | 25 | $9,201 |
| Corcept Therapeutics | 16 | $3,514 |
| Medtronic(2 entities) | 25 | $536 |
| Novo Nordisk | 38 | $429 |
| AstraZeneca | 11 | $261 |
| Abbott | 4 | $215 |
| Amarin Pharma, Inc. | 5 | $173 |
| Lilly USA, LLC | 5 | $127 |
| Dexcom, Inc. | 2 | $64 |
| Mannkind Corporation | 4 | $63 |
| Xeris Pharmaceuticals, Inc. | 4 | $60 |
| Boehringer Ingelheim | 3 | $51 |
| Ascendis Pharma Endocrinology Inc | 1 | $48 |
| Insulet Corporation | 2 | $30 |
| Merck | 2 | $26 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| AbbVie | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$12,388
- TEPEZZA$8,464
- TOUJEO$6,437
- Korlym$3,403
- EVENITY$363
- MINIMED 780G$145
- Vascepa$141
- Saxenda$125
How this compares
$34,385 in reported general payments places this provider in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $143,436 |
| TrulicityDulaglutide | 79 | $122,885 |
| JardianceEmpagliflozin | 85 | $118,737 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 100 | $86,715 |
| MounjaroTirzepatide | 46 | $74,953 |
| RybelsusSemaglutide | 34 | $74,247 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 42 | $57,241 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $40,471 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 19 | $36,881 |
| FarxigaDapagliflozin Propanediol | 15 | $21,695 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $19,299 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $17,417 |
| Cinacalcet Hcl | 59 | $16,322 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 101 | $14,539 |
| NovologInsulin Aspart | 38 | $12,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $429 | $266,700193 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $127 | $208,099154 claims |
| Boehringer IngelheimJardiance | $51 | $118,73785 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $19,492 | $63,94769 claims |
| AstraZenecaFarxiga | $261 | $21,69515 claims |
| MerckJanuvia, Janumet Xr | $26 | $13,87627 claims |
| AbbVieSynthroid, Armour Thyroid | $19 | $9,54897 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Cottonwood
- Muhammad SethiTucson$670K
- Kevin YuenPhoenix$404K
- Amir HarariScottsdale$361K
- Joan BaileyPhoenix$316K
- Kristina BlohmScottsdale$220K
- Karen HerbstTucson$200K
- Laura KnechtCave Creek$142K
- Andrea FerencziScottsdale$132K
- Nora BarsonyTucson$121K
- Vidhyalakshmi KannanMesa$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.